Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials.

Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials. JAMA Cardiol. 2017 02 01; 2(2):127-135.

View in: PubMed

subject areas

Adenosine Monophosphate
Adult
Aged
Aged, 80 and over
Dose-Response Relationship, Drug
Double-Blind Method
Female
Follow-Up Studies
Hemorrhage
Humans
Incidence
Injections, Intravenous
Male
Middle Aged
Myocardial Infarction
Platelet Aggregation Inhibitors
Platelet Glycoprotein GPIIb-IIIa Complex
Prospective Studies
Purinergic P2Y Receptor Antagonists
Risk Factors
Survival Rate
Treatment Outcome
United States

authors with profiles

Robert Harrington